End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
745,000 KRW | -1.32% | -5.70% | -1.97% |
05-23 | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
05-06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.97% | 39.5B | |
-1.64% | 90.28B | |
-16.00% | 31.71B | |
+61.28% | 26.41B | |
-22.82% | 14.34B | |
-9.30% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B | |
-13.92% | 7.53B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe